Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ASSEMBLY BIOSCIENCES, INC.ASMB · Entity 5216 | Director | May 20, 2021 | May 24, 2021 |
| CITIUS ONCOLOGY, INC.CTOR · Entity 6935 | Director · Secretary | September 19, 2025 | December 22, 2025 |
| Citius Pharmaceuticals, Inc.CTXR · Entity 7778 | Director · Vice Chairman | August 08, 2025 | August 12, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ASSEMBLY BIOSCIENCES, INC.
Report date May 20, 2021 · Filed May 24, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.03 · Expires 2031-05-20 | Direct | 15,000 |
Reported balance
After 2021-05-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-05-20 · Grant · Acquired 15,000 · Balance 15,000 F1: Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) May 20, 2022 and (2) the date of the Issuer's 2022 annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) May 20, 2022 and (2) the date of the Issuer's 2022 annual meeting of stockholders.
CITIUS ONCOLOGY, INC.
Report date September 19, 2025 · Filed December 22, 2025 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 850,000 |
Reported balance
After 2025-09-19 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2025-09-19 · Grant · Acquired 850,000 · Balance 850,000 F1: Represents restricted stock units granted on September 19, 2025. The shares underlying the restricted stock units will vest in full on the third anniversary of the grant date, subject to the Reporting Person's Continuous Service to Citius Oncology, Inc. (the "Company") or a Related Entity (as defined in the award agreement) as of the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units granted on September 19, 2025. The shares underlying the restricted stock units will vest in full on the third anniversary of the grant date, subject to the Reporting Person's Continuous Service to Citius Oncology, Inc. (the "Company") or a Related Entity (as defined in the award agreement) as of the applicable vesting date.
Citius Pharmaceuticals, Inc.
Report date August 08, 2025 · Filed August 12, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Warrant to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $28.75 · Expires 2025-08-14 | Direct | 0 |
Reported balance
After 2025-08-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-08-08 · Disposition to issuer · Disposed 31,373 · Balance 0 F1: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from August 14, 2025 to August 14, 2026, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on August 13, 2018 and was exercisable immediately. |
| Warrant to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $28.75 · Expires 2026-08-14 | Direct | 31,373 |
Reported balance
After 2025-08-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-08-08 · Grant · Acquired 31,373 · Balance 31,373 F1: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from August 14, 2025 to August 14, 2026, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on August 13, 2018 and was exercisable immediately. |
| Warrant to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $19.25 · Expires 2025-09-27 | Direct | 0 |
Reported balance
After 2025-08-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-08-08 · Disposition to issuer · Disposed 22,344 · Balance 0 F2: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from September 27, 2025 to September 27, 2026, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on September 27, 2019 and was exercisable immediately. |
| Warrant to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $19.25 · Expires 2026-09-27 | Direct | 22,344 |
Reported balance
After 2025-08-08 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-08-08 · Grant · Acquired 22,344 · Balance 22,344 F4: The options are held by the Reporting Person's daughter. The Reporting Person disclaims beneficial ownership in these shares. F2: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from September 27, 2025 to September 27, 2026, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on September 27, 2019 and was exercisable immediately. |
| Common StockSEC Table I · non-derivative | Direct | 79,690 |
Reported balance
Holding disclosure · report date 2025-08-08 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 79,690 |
| Stock Option (Right to Purchase Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $9.50 · Expires 2034-11-07 | Direct | 14,000 |
Reported balance
Holding disclosure · report date 2025-08-08 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 14,000 F3: The options were granted on November 7, 2024. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date. |
| Stock Option (Right to Purchase Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $17.50 · Expires 2033-10-10 | Direct | 16,000 |
Reported balance
Holding disclosure · report date 2025-08-08 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 16,000 F5: The options were granted on October 10, 2023. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date. |
| Stock Option (Right to Purchase Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $31.25 · Expires 2032-10-04 | Direct | 16,000 |
Reported balance
Holding disclosure · report date 2025-08-08 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 16,000 F6: The options were granted on October 4, 2022. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date. |
| Stock Option (Right to Purchase Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $51.00 · Expires 2031-10-11 | Direct | 26,000 |
Reported balance
Holding disclosure · report date 2025-08-08 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 26,000 F7: The options are vested in full and exercisable immediately. |
| Stock Option (Right to Purchase Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $50.00 · Expires 2031-07-22 | Direct | 12,000 |
Reported balance
Holding disclosure · report date 2025-08-08 · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · Balance 12,000 F7: The options are vested in full and exercisable immediately. |
| Stock Option (Right to Purchase Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $25.25 · Expires 2030-10-06 | Direct | 8,000 |
Reported balance
Holding disclosure · report date 2025-08-08 · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · Balance 8,000 F7: The options are vested in full and exercisable immediately. |
| Stock Option (Right to Purchase Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $16.75 · Expires 2029-10-08 | Direct | 7,000 |
Reported balance
Holding disclosure · report date 2025-08-08 · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · Balance 7,000 F7: The options are vested in full and exercisable immediately. |
| Stock Option (Right to Purchase Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $40.50 · Expires 2028-09-04 | Direct | 6,000 |
Reported balance
Holding disclosure · report date 2025-08-08 · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · Balance 6,000 F7: The options are vested in full and exercisable immediately. |
| Stock Option (Right to Purchase Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $86.25 · Expires 2027-09-13 | Direct | 1,600 |
Reported balance
Holding disclosure · report date 2025-08-08 · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · Balance 1,600 F7: The options are vested in full and exercisable immediately. |
| Stock Option (Right to Purchase Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $202.50 · Expires 2025-10-01 | Direct | 1,067 |
Reported balance
Holding disclosure · report date 2025-08-08 · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · Balance 1,067 F7: The options are vested in full and exercisable immediately. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.50 · Expires 2034-11-07 | IndirectSee footnote | 3,000 |
Reported balance
Holding disclosure · report date 2025-08-08 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 3,000 F4: The options are held by the Reporting Person's daughter. The Reporting Person disclaims beneficial ownership in these shares. |
| Stock Option (Right to Purchase Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $51.00 · Expires 2031-10-11 | IndirectSee footnote | 600 |
Reported balance
Holding disclosure · report date 2025-08-08 · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · Balance 600 F4: The options are held by the Reporting Person's daughter. The Reporting Person disclaims beneficial ownership in these shares. |
| Stock Option (Right to Purchase Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $50.00 · Expires 2031-07-22 | IndirectSee footnote | 400 |
Reported balance
Holding disclosure · report date 2025-08-08 · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · Balance 400 F4: The options are held by the Reporting Person's daughter. The Reporting Person disclaims beneficial ownership in these shares. |
Filing footnotes · ownership attribution and instrument terms
F1: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from August 14, 2025 to August 14, 2026, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on August 13, 2018 and was exercisable immediately.
F2: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from September 27, 2025 to September 27, 2026, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on September 27, 2019 and was exercisable immediately.
F3: The options were granted on November 7, 2024. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date.
F4: The options are held by the Reporting Person's daughter. The Reporting Person disclaims beneficial ownership in these shares.
F5: The options were granted on October 10, 2023. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date.
F6: The options were granted on October 4, 2022. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date.
F7: The options are vested in full and exercisable immediately.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 19, 2025 Filed Sep 23, 2025 20:10 UTC | CITIUS ONCOLOGY, INC. CTOR · Entity 6935 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-090617 · ownership.xml · nonDerivative · entry 2 HOLUBIAK MYRON Z · CIK 0001199080 · Director · Secretary 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 100,000 F2 · ownership.nature: Represents restricted stock awards granted on September 19, 2025 to the Reporting Person's daughter. The Reporting Person disclaims beneficial ownership in these shares. Read SEC document |
| September 19, 2025 Filed Sep 23, 2025 20:10 UTC | CITIUS ONCOLOGY, INC. CTOR · Entity 6935 | GrantCommon Stock | 850,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-090617 · ownership.xml · nonDerivative · entry 1 HOLUBIAK MYRON Z · CIK 0001199080 · Director · Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 850,000 F1 · shares: Represents restricted stock awards granted on September 19, 2025. The shares will vest in three substantially equal installments on the first, second and third anniversaries of the grant date, subject to the Reporting Person's Continuous Service to Citius Oncology, Inc. (the "Company") or a Related Entity (as defined in the award agreement) as of the applicable vesting date. Read SEC document |
| September 19, 2025 Filed Dec 1, 2025 21:10 UTC Amendment | CITIUS ONCOLOGY, INC. CTOR · Entity 6935 | GrantCommon Stock | 850,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-116678 · ownership.xml · nonDerivative · entry 1 HOLUBIAK MYRON Z · CIK 0001199080 · Director · Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 850,000 F1 · shares: Represents restricted stock awards granted on September 19, 2025. The shares will vest in full on the third anniversary of the grant date, subject to the Reporting Person's Continuous Service to Citius Oncology, Inc. (the "Company") or a Related Entity (as defined in the award agreement) as of the applicable vesting date. Read SEC document |
| September 19, 2025 Filed Dec 22, 2025 21:10 UTC Amendment | CITIUS ONCOLOGY, INC. CTOR · Entity 6935 | GrantCommon Stock | 850,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-124536 · ownership.xml · nonDerivative · entry 1 HOLUBIAK MYRON Z · CIK 0001199080 · Director · Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 850,000 F1 · shares: Represents restricted stock units granted on September 19, 2025. The shares underlying the restricted stock units will vest in full on the third anniversary of the grant date, subject to the Reporting Person's Continuous Service to Citius Oncology, Inc. (the "Company") or a Related Entity (as defined in the award agreement) as of the applicable vesting date. Read SEC document |
| August 08, 2025 Filed Aug 12, 2025 16:51 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | GrantWarrant to Purchase Common Stock · Derivative | 22,344 | Not disclosed Strike: $19.25 | Not disclosed |
DisclosureSEC source: 0001213900-25-075035 · ownership.xml · derivative · entry 5 HOLUBIAK MYRON Z · CIK 0001199080 · Director · Vice Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,344 Underlying: Common Stock · 22,344 shares Expires 2026-09-27 F4 · security: The options are held by the Reporting Person's daughter. The Reporting Person disclaims beneficial ownership in these shares. F2 · kind: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from September 27, 2025 to September 27, 2026, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on September 27, 2019 and was exercisable immediately. F2 · price: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from September 27, 2025 to September 27, 2026, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on September 27, 2019 and was exercisable immediately. F2 · derivative.exercise_date: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from September 27, 2025 to September 27, 2026, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on September 27, 2019 and was exercisable immediately. Read SEC document |
| August 08, 2025 Filed Aug 12, 2025 16:51 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | Disposition to issuerWarrant to Purchase Common Stock · Derivative | 22,344 | Not disclosed Strike: $19.25 | Not disclosed |
DisclosureSEC source: 0001213900-25-075035 · ownership.xml · derivative · entry 4 HOLUBIAK MYRON Z · CIK 0001199080 · Director · Vice Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,344 shares Expires 2025-09-27 F2 · security: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from September 27, 2025 to September 27, 2026, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on September 27, 2019 and was exercisable immediately. F2 · kind: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from September 27, 2025 to September 27, 2026, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on September 27, 2019 and was exercisable immediately. F2 · price: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from September 27, 2025 to September 27, 2026, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on September 27, 2019 and was exercisable immediately. F2 · derivative.exercise_date: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from September 27, 2025 to September 27, 2026, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on September 27, 2019 and was exercisable immediately. Read SEC document |
| August 08, 2025 Filed Aug 12, 2025 16:51 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | GrantWarrant to Purchase Common Stock · Derivative | 31,373 | Not disclosed Strike: $28.75 | Not disclosed |
DisclosureSEC source: 0001213900-25-075035 · ownership.xml · derivative · entry 3 HOLUBIAK MYRON Z · CIK 0001199080 · Director · Vice Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,373 Underlying: Common Stock · 31,373 shares Expires 2026-08-14 F1 · security: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from August 14, 2025 to August 14, 2026, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on August 13, 2018 and was exercisable immediately. F1 · kind: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from August 14, 2025 to August 14, 2026, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on August 13, 2018 and was exercisable immediately. F1 · price: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from August 14, 2025 to August 14, 2026, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on August 13, 2018 and was exercisable immediately. F1 · derivative.exercise_date: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from August 14, 2025 to August 14, 2026, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on August 13, 2018 and was exercisable immediately. Read SEC document |
| August 08, 2025 Filed Aug 12, 2025 16:51 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | Disposition to issuerWarrant to Purchase Common Stock · Derivative | 31,373 | Not disclosed Strike: $28.75 | Not disclosed |
DisclosureSEC source: 0001213900-25-075035 · ownership.xml · derivative · entry 2 HOLUBIAK MYRON Z · CIK 0001199080 · Director · Vice Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 31,373 shares Expires 2025-08-14 F1 · security: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from August 14, 2025 to August 14, 2026, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on August 13, 2018 and was exercisable immediately. F1 · kind: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from August 14, 2025 to August 14, 2026, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on August 13, 2018 and was exercisable immediately. F1 · price: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from August 14, 2025 to August 14, 2026, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on August 13, 2018 and was exercisable immediately. F1 · derivative.exercise_date: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from August 14, 2025 to August 14, 2026, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on August 13, 2018 and was exercisable immediately. Read SEC document |
| December 12, 2024 Filed Dec 16, 2024 21:09 UTC | CITIUS ONCOLOGY, INC. CTOR · Entity 6935 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $1.07 | $0.00 |
DisclosureSEC source: 0001213900-24-109304 · ownership.xml · derivative · entry 2 HOLUBIAK MYRON Z · CIK 0001199080 · Director · Secretary 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2034-12-12 F2 · derivative.exercise_date: These options are held by the Reporting Person's daughter. The Reporting Person disclaims beneficial ownership in these shares. F2 · ownership.nature: These options are held by the Reporting Person's daughter. The Reporting Person disclaims beneficial ownership in these shares. Read SEC document |
| December 12, 2024 Filed Dec 16, 2024 21:09 UTC | CITIUS ONCOLOGY, INC. CTOR · Entity 6935 | GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $1.07 | $0.00 |
DisclosureSEC source: 0001213900-24-109304 · ownership.xml · derivative · entry 1 HOLUBIAK MYRON Z · CIK 0001199080 · Director · Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2034-12-12 F1 · derivative.exercise_date: These options were granted December 12, 2024. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the grant date, provided that Optionee provides Continuous Service to the Company as of each such vesting date. Read SEC document |
| November 07, 2024 Filed Nov 12, 2024 17:00 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $0.38 | $0.00 |
DisclosureSEC source: 0001213900-24-096888 · ownership.xml · derivative · entry 3 HOLUBIAK MYRON Z · CIK 0001199080 · Director · Vice Chairman 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2034-11-07 F2 · derivative.exercise_date: The options are held by the Reporting Person's daughter. The Reporting Person disclaims beneficial ownership in these shares. F2 · ownership.nature: The options are held by the Reporting Person's daughter. The Reporting Person disclaims beneficial ownership in these shares. Read SEC document |
| November 07, 2024 Filed Nov 12, 2024 17:00 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | GrantStock Option (Right to Purchase Common Stock) · Derivative | 350,000 | $0.00 Strike: $0.38 | $0.00 |
DisclosureSEC source: 0001213900-24-096888 · ownership.xml · derivative · entry 2 HOLUBIAK MYRON Z · CIK 0001199080 · Director · Vice Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2034-11-07 F1 · derivative.exercise_date: The options were granted on November 7, 2024. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date. Read SEC document |
| September 25, 2024 Filed Sep 27, 2024 17:27 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | GrantWarrant to Purchase Common Stock · Derivative | 558,597 | Not disclosed Strike: $0.77 | Not disclosed |
DisclosureSEC source: 0001213900-24-082813 · ownership.xml · derivative · entry 5 HOLUBIAK MYRON Z · CIK 0001199080 · Director · Vice Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 558,597 Underlying: Common Stock · 558,597 shares Expires 2025-09-27 F2 · security: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from September 27, 2024 to September 27, 2025, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on September 27, 2019 and was exercisable immediately. F2 · kind: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from September 27, 2024 to September 27, 2025, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on September 27, 2019 and was exercisable immediately. F2 · price: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from September 27, 2024 to September 27, 2025, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on September 27, 2019 and was exercisable immediately. F2 · derivative.exercise_date: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from September 27, 2024 to September 27, 2025, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on September 27, 2019 and was exercisable immediately. Read SEC document |
| September 25, 2024 Filed Sep 27, 2024 17:27 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | Disposition to issuerWarrant to Purchase Common Stock · Derivative | 558,597 | Not disclosed Strike: $0.77 | Not disclosed |
DisclosureSEC source: 0001213900-24-082813 · ownership.xml · derivative · entry 4 HOLUBIAK MYRON Z · CIK 0001199080 · Director · Vice Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 558,597 shares Expires 2024-09-27 F2 · security: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from September 27, 2024 to September 27, 2025, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on September 27, 2019 and was exercisable immediately. F2 · kind: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from September 27, 2024 to September 27, 2025, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on September 27, 2019 and was exercisable immediately. F2 · price: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from September 27, 2024 to September 27, 2025, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on September 27, 2019 and was exercisable immediately. F2 · derivative.exercise_date: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from September 27, 2024 to September 27, 2025, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on September 27, 2019 and was exercisable immediately. Read SEC document |
| August 14, 2024 Filed Sep 27, 2024 17:27 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | GrantWarrant to Purchase Common Stock · Derivative | 784,314 | Not disclosed Strike: $1.15 | Not disclosed |
DisclosureSEC source: 0001213900-24-082813 · ownership.xml · derivative · entry 3 HOLUBIAK MYRON Z · CIK 0001199080 · Director · Vice Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 784,314 Underlying: Common Stock · 784,314 shares Expires 2025-08-14 F1 · security: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from August 14, 2024 to August 14, 2025, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on August 13, 2018 and was exercisable immediately. F1 · kind: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from August 14, 2024 to August 14, 2025, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on August 13, 2018 and was exercisable immediately. F1 · price: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from August 14, 2024 to August 14, 2025, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on August 13, 2018 and was exercisable immediately. F1 · derivative.exercise_date: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from August 14, 2024 to August 14, 2025, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on August 13, 2018 and was exercisable immediately. Read SEC document |
| August 14, 2024 Filed Sep 27, 2024 17:27 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | Disposition to issuerWarrant to Purchase Common Stock · Derivative | 784,314 | Not disclosed Strike: $1.15 | Not disclosed |
DisclosureSEC source: 0001213900-24-082813 · ownership.xml · derivative · entry 2 HOLUBIAK MYRON Z · CIK 0001199080 · Director · Vice Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 784,314 shares Expires 2024-08-14 F1 · security: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from August 14, 2024 to August 14, 2025, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on August 13, 2018 and was exercisable immediately. F1 · kind: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from August 14, 2024 to August 14, 2025, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on August 13, 2018 and was exercisable immediately. F1 · price: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from August 14, 2024 to August 14, 2025, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on August 13, 2018 and was exercisable immediately. F1 · derivative.exercise_date: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from August 14, 2024 to August 14, 2025, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on August 13, 2018 and was exercisable immediately. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 22:28 UTC | CITIUS ONCOLOGY, INC. CTOR · Entity 6935 | GrantStock Option (Right to Buy) · Derivative | 500,000 | $0.00 Strike: $2.15 | $0.00 |
DisclosureSEC source: 0001213900-24-069250 · ownership.xml · derivative · entry 1 HOLUBIAK MYRON Z · CIK 0001199080 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2033-07-05 F1 · derivative.exercise_date: This option, originally issued by Citius Oncology Sub, Inc., vests over three years, beginning July 5, 2023, with 1/36th every month for the first year, and the 1/3 each on the second and third anniversary of the July 5, 2023, provided that the Reporting Person provides continuous services to Citius Oncology Sub, Inc. or a related entity as of each such vesting date. The option was assumed by Citius Oncology, Inc. in the merger transaction, which closed August 12, 2024. Read SEC document |
| August 12, 2024 Filed Aug 30, 2024 20:05 UTC Amendment | CITIUS ONCOLOGY, INC. CTOR · Entity 6935 | GrantStock Option (Right to Buy) · Derivative | 1,500,000 | $0.00 Strike: $2.15 | $0.00 |
DisclosureSEC source: 0001213900-24-074518 · ownership.xml · derivative · entry 1 HOLUBIAK MYRON Z · CIK 0001199080 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,500,000 Underlying: Common Stock · 1,500,000 shares Expires 2033-07-05 F1 · derivative.exercise_date: This option, originally issued by Citius Oncology Sub, Inc., vests over three years, beginning July 5, 2023, with 1/36th every month for the first year, and the 1/3 each on the second and third anniversary of the July 5, 2023, provided that the Reporting Person provides continuous services to Citius Oncology Sub, Inc. or a related entity as of each such vesting date. The option was assumed by Citius Oncology, Inc. in the merger transaction, which closed August 12, 2024. F2 · balance_after: This Form 4 has been amended to correct the amount of option shares held by the Reporting Person. Read SEC document |
| April 03, 2024 Filed Apr 5, 2024 16:05 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | GrantWarrant to Purchase Common Stock · Derivative | 129,450 | Not disclosed Strike: $1.42 | Not disclosed |
DisclosureSEC source: 0001213900-24-030812 · ownership.xml · derivative · entry 3 HOLUBIAK MYRON Z · CIK 0001199080 · Director · Vice Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 129,450 Underlying: Common Stock · 129,450 shares Expires 2025-04-05 F1 · security: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from April 5, 2024 to April 5, 2025, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on April 3, 2019 and was exercisable immediately. F1 · kind: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from April 5, 2024 to April 5, 2025, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on April 3, 2019 and was exercisable immediately. F1 · price: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from April 5, 2024 to April 5, 2025, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on April 3, 2019 and was exercisable immediately. F1 · derivative.exercise_date: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from April 5, 2024 to April 5, 2025, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on April 3, 2019 and was exercisable immediately. Read SEC document |
| April 03, 2024 Filed Apr 5, 2024 16:05 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | Disposition to issuerWarrant to Purchase Common Stock · Derivative | 129,450 | Not disclosed Strike: $1.42 | Not disclosed |
DisclosureSEC source: 0001213900-24-030812 · ownership.xml · derivative · entry 2 HOLUBIAK MYRON Z · CIK 0001199080 · Director · Vice Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 129,450 shares Expires 2024-04-05 F1 · security: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from April 5, 2024 to April 5, 2025, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on April 3, 2019 and was exercisable immediately. F1 · kind: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from April 5, 2024 to April 5, 2025, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on April 3, 2019 and was exercisable immediately. F1 · price: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from April 5, 2024 to April 5, 2025, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on April 3, 2019 and was exercisable immediately. F1 · derivative.exercise_date: The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from April 5, 2024 to April 5, 2025, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on April 3, 2019 and was exercisable immediately. Read SEC document |
| October 10, 2023 Filed Oct 12, 2023 16:15 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | GrantOptions to Purchase Common Stock · Derivative | 400,000 | $0.00 Strike: $0.70 | $0.00 |
DisclosureSEC source: 0001013762-23-003533 · ownership.xml · derivative · entry 15 HOLUBIAK MYRON Z · CIK 0001199080 · Director · Vice Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2033-10-10 F11 · security: The options were granted on October 10, 2023. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date. F11 · derivative.exercise_date: The options were granted on October 10, 2023. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date. Read SEC document |
| October 04, 2022 Filed Oct 6, 2022 16:08 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | GrantOptions to Purchase Common Stock · Derivative | 400,000 | $0.00 Strike: $1.25 | $0.00 |
DisclosureSEC source: 0001213900-22-062483 · ownership.xml · derivative · entry 14 HOLUBIAK MYRON Z · CIK 0001199080 · Director · Vice Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2032-10-04 F11 · security: The options were granted on October 4, 2022. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date. F11 · derivative.exercise_date: The options were granted on October 4, 2022. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date. Read SEC document |
| October 11, 2021 Filed Oct 13, 2021 17:25 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | GrantOptions to Purchase Common Stock · Derivative | 15,000 | $0.00 Strike: $2.04 | $0.00 |
DisclosureSEC source: 0001213900-21-052678 · ownership.xml · derivative · entry 13 HOLUBIAK MYRON Z · CIK 0001199080 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-10-11 F9 · security: The options are held by the Reporting Person's daughter. The Reporting Person disclaims beneficial ownership in these shares. F10 · derivative.exercise_date: The options were granted on October 11, 2021. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date. F9 · ownership.nature: The options are held by the Reporting Person's daughter. The Reporting Person disclaims beneficial ownership in these shares. Read SEC document |
| October 11, 2021 Filed Oct 13, 2021 17:25 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | GrantOptions to Purchase Common Stock · Derivative | 650,000 | $0.00 Strike: $2.04 | $0.00 |
DisclosureSEC source: 0001213900-21-052678 · ownership.xml · derivative · entry 12 HOLUBIAK MYRON Z · CIK 0001199080 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 650,000 Underlying: Common Stock · 650,000 shares Expires 2031-10-11 F10 · security: The options were granted on October 11, 2021. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date. F10 · derivative.exercise_date: The options were granted on October 11, 2021. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date. Read SEC document |
| July 22, 2021 Filed Jul 26, 2021 17:02 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | GrantOptions to Purchase Common Stock · Derivative | 10,000 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0001213900-21-038696 · ownership.xml · derivative · entry 11 HOLUBIAK MYRON Z · CIK 0001199080 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-07-22 F9 · security: The options are held by the Reporting Person's daughter. The Reporting Person disclaims beneficial ownership in these shares. F8 · derivative.exercise_date: The options were granted on July 22, 2021. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date. F9 · ownership.nature: The options are held by the Reporting Person's daughter. The Reporting Person disclaims beneficial ownership in these shares. Read SEC document |
| July 22, 2021 Filed Jul 26, 2021 17:02 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | GrantOptions to Purchase Common Stock · Derivative | 300,000 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0001213900-21-038696 · ownership.xml · derivative · entry 10 HOLUBIAK MYRON Z · CIK 0001199080 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2031-07-22 F8 · security: The options were granted on July 22, 2021. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date. F8 · derivative.exercise_date: The options were granted on July 22, 2021. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date. Read SEC document |
| May 20, 2021 Filed May 24, 2021 20:59 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $4.03 | $0.00 |
DisclosureSEC source: 0001209191-21-035388 · doc4.xml · derivative · entry 1 HOLUBIAK MYRON Z · CIK 0001199080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-05-20 F1 · derivative.exercise_date: Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) May 20, 2022 and (2) the date of the Issuer's 2022 annual meeting of stockholders. Read SEC document |
| October 06, 2020 Filed Oct 9, 2020 16:08 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | GrantOptions to Purchase Common Stock · Derivative | 200,000 | $0.00 Strike: $1.01 | $0.00 |
DisclosureSEC source: 0001213900-20-030794 · ownership.xml · derivative · entry 9 HOLUBIAK MYRON Z · CIK 0001199080 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2030-10-06 F7 · security: The options were granted on October 6, 2020. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date. F7 · derivative.exercise_date: The options were granted on October 6, 2020. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date. Read SEC document |
| June 11, 2020 Filed Jun 15, 2020 20:41 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $20.47 | $0.00 |
DisclosureSEC source: 0001209191-20-036632 · doc4.xml · derivative · entry 1 HOLUBIAK MYRON Z · CIK 0001199080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-06-11 F1 · derivative.exercise_date: Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) June 11, 2021 and (2) the date of the Issuer's 2021 annual meeting of stockholders. Read SEC document |
| October 08, 2019 Filed Oct 10, 2019 16:09 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | GrantOptions to Purchase Common Stock · Derivative | 175,000 | $0.00 Strike: $0.67 | $0.00 |
DisclosureSEC source: 0001213900-19-020115 · ownership.xml · derivative · entry 9 HOLUBIAK MYRON Z · CIK 0001199080 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2029-10-08 F6 · derivative.exercise_date: The options were granted on October 8, 2019. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date. Read SEC document |
| September 27, 2019 Filed Sep 27, 2019 16:15 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | PurchaseWarrant to Purchase Common Stock · Derivative | 558,597 | Not disclosed Strike: $0.77 | Not disclosed |
DisclosureSEC source: 0001213900-19-019177 · ownership.xml · derivative · entry 8 HOLUBIAK MYRON Z · CIK 0001199080 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 558,597 Underlying: Common Stock · 558,597 shares Expires 2024-09-27 F1 · security: The warrant is fully vested and exercisable immediately. F2 · price: The purchase price of the warrants was included in the purchase price of the common stock reported in Table I. F1 · derivative.exercise_date: The warrant is fully vested and exercisable immediately. Read SEC document |
| September 27, 2019 Filed Sep 27, 2019 16:15 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | PurchaseCommon Stock | 558,597 | $0.90 | $500,000.17 |
DisclosureSEC source: 0001213900-19-019177 · ownership.xml · nonDerivative · entry 1 HOLUBIAK MYRON Z · CIK 0001199080 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,992,243 Read SEC document |
| May 17, 2019 Filed May 17, 2019 23:33 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $15.22 | $0.00 |
DisclosureSEC source: 0001144204-19-027158 · tv521924_4.xml · derivative · entry 1 HOLUBIAK MYRON Z · CIK 0001199080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-05-17 F1 · derivative.exercise_date: The shares of common stock underlying the option will vest upon the earlier of (i) May 17, 2020 and (ii) the date of the Issuer's 2020 annual meeting of stockholders. Read SEC document |
| April 03, 2019 Filed Apr 5, 2019 16:06 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | PurchaseWarrant to Purchase Common Stock · Derivative | 129,450 | Not disclosed Strike: $1.42 | Not disclosed |
DisclosureSEC source: 0001213900-19-005843 · ownership.xml · derivative · entry 7 HOLUBIAK MYRON Z · CIK 0001199080 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,450 Underlying: Common Stock · 129,450 shares Expires 2021-04-05 F1 · security: The warrant is fully vested and exercisable immediately. F2 · price: The purchase price of the warrants was included in the purchase price of the common stock reported in Table I. F1 · derivative.exercise_date: The warrant is fully vested and exercisable immediately. Read SEC document |
| April 03, 2019 Filed Apr 5, 2019 16:06 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | PurchaseCommon Stock | 129,450 | $1.55 | $200,000.25 |
DisclosureSEC source: 0001213900-19-005843 · ownership.xml · nonDerivative · entry 1 HOLUBIAK MYRON Z · CIK 0001199080 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,433,646 Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 16:10 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | GrantOptions to Purchase Common Stock · Derivative | 150,000 | $0.00 Strike: $1.62 | $0.00 |
DisclosureSEC source: 0001213900-18-012192 · ownership.xml · derivative · entry 6 HOLUBIAK MYRON Z · CIK 0001199080 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2028-09-04 F5 · security: One-third of the shares of the Company's common stock underlying the grant vest on each of the one-year, two-year and three-year anniversary of the vesting commencement date, September 4, 2018, provided that the Reporting Person provides continuous services to the Company as of each such vesting date. F5 · derivative.exercise_date: One-third of the shares of the Company's common stock underlying the grant vest on each of the one-year, two-year and three-year anniversary of the vesting commencement date, September 4, 2018, provided that the Reporting Person provides continuous services to the Company as of each such vesting date. Read SEC document |
| August 13, 2018 Filed Aug 15, 2018 17:06 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | GrantWarrant to Purchase Common Stock · Derivative | 784,314 | Not disclosed Strike: $1.15 | Not disclosed |
DisclosureSEC source: 0001213900-18-011211 · ownership.xml · derivative · entry 2 HOLUBIAK MYRON Z · CIK 0001199080 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 784,314 Underlying: Common Stock · 784,314 shares Expires 2023-08-14 F1 · security: The warrant is fully vested and exercisable immediately. F2 · price: The purchase price of the warrants was included in the purchase price of the common stock reported in Table I. F1 · derivative.exercise_date: The warrant is fully vested and exercisable immediately. Read SEC document |
| August 13, 2018 Filed Aug 15, 2018 17:06 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | PurchaseCommon Stock | 784,314 | $1.28 | $1,000,000.35 |
DisclosureSEC source: 0001213900-18-011211 · ownership.xml · nonDerivative · entry 1 HOLUBIAK MYRON Z · CIK 0001199080 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,304,196 Read SEC document |
| May 30, 2018 Filed Jun 1, 2018 21:46 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $42.09 | $0.00 |
DisclosureSEC source: 0001144204-18-032470 · tv495555_4.xml · derivative · entry 1 HOLUBIAK MYRON Z · CIK 0001199080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2028-05-30 F1 · derivative.exercise_date: The shares of common stock underlying the option will vest upon the earlier of (i) May 30, 2019 and (ii) the date of the Issuer's 2019 annual meeting of stockholders. Read SEC document |
| March 28, 2018 Filed Mar 29, 2018 18:00 UTC | Citius Pharmaceuticals, Inc. CTXR · Entity 7778 | PurchaseCommon Stock | 2,915 | $3.09 | $9,007.35 |
DisclosureSEC source: 0001213900-18-003691 · f4032818holubiak_citiuspharm.xml · nonDerivative · entry 1 HOLUBIAK MYRON Z · CIK 0001199080 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 519,882 Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 20:31 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $25.96 | $0.00 |
DisclosureSEC source: 0001144204-17-031032 · v468318_4.xml · derivative · entry 1 HOLUBIAK MYRON Z · CIK 0001199080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2027-06-01 F1 · derivative.exercise_date: The shares of Common Stock underlying the option will vest upon the earlier of (i) June 1, 2018 and (ii) the date of the Issuer's 2018 annual meeting of stockholders. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.